Tris<-N-(benzyloxy)amino>butyl> isocyanurate | 153756-35-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: Tris<-N-(benzyloxy)amino>butyl> isocyanurate
• 英文别名: Tris({N-[(trichloroethoxy)carbonyl]-N-(benzyloxy)amino}butyl) isocyanurate；2,2,2-trichloroethyl N-phenylmethoxy-N-[4-[2,4,6-trioxo-3,5-bis[4-[phenylmethoxy(2,2,2-trichloroethoxycarbonyl)amino]butyl]-1,3,5-triazinan-1-yl]butyl]carbamate
• CAS: 153756-35-5
• 化学式: C₄₅H₅₁Cl₉N₆O₁₂
• 分子量: 1187.01
• InChiKey: GGFFETMLQIYSCK-UHFFFAOYSA-N

物化性质

• 沸点：
  1020.3±65.0 °C(predicted)
• 密度：
  1.456±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11.4
• 重原子数：
  72
• 可旋转键数：
  30
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  177
• 氢给体数：
  0
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  Tris<-N-(benzyloxy)amino>butyl> isocyanurate 在 4-二甲氨基吡啶 、 N-羟基-7-氮杂苯并三氮唑 、 溶剂黄146 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 锌 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.83h， 生成 [bis[N-(trichloroethoxy)carbonyl]mono[N-succinoyl](benzyloxy)amino butyl] isocyanurate
  参考文献：
  名称：

  Syntheses and studies of multiwarhead siderophore-5-fluorouridine conjugates

  摘要：

  Siderophores are microbial iron chelating agents that: sequester physiologically essential iron for microbes. Conjugation of drugs to siderophores allows use of active iron transport for microbially directed drug delivery. Syntheses and biological studies are described of the first multidrug isocyanurate-based siderophore analogues separately containing one, two, and three 5-fluorouridine (5-FU) derivatives as the drug component. The results indicate that a single siderophore can be used to deliver multiple drugs to target pathogenic microorganisms. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00248-5
• 作为产物：
  描述：

  O-benzyl-N-((trichloroethoxy)carbonyl)hydroxylamine 在 sodium hydride 、 sodium iodide 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.25h， 生成 Tris<-N-(benzyloxy)amino>butyl> isocyanurate
  参考文献：
  名称：

  Iron Transport-Mediated Drug Delivery: Synthesis and Biological Evaluation of Cyanuric Acid-Based Siderophore Analogs and .beta.-Lactam Conjugates

  摘要：

  Trihydroxamate-containing isocyanurates 4a-c were synthesized and determined to be capable of substituting for natural siderophores (microbial iron sequestering agents) in limited microbiological assays. The direct coupling of protected 4a to carbacephalosporins 16 and 17 and subsequent deprotection gave conjugates 20 and 21. The Lorabid conjugate 21 was especially active against E. coli X580 in preliminary biological tests, thus demonstrating the continued potential of siderophore-mediated drug delivery.

  DOI：

  10.1021/jo00084a018

文献信息

• Syntheses and studies of multiwarhead siderophore-5-fluorouridine conjugates
  作者：Yong Lu、Marvin J Miller

  DOI：10.1016/s0968-0896(99)00248-5

  日期：1999.12

  Siderophores are microbial iron chelating agents that: sequester physiologically essential iron for microbes. Conjugation of drugs to siderophores allows use of active iron transport for microbially directed drug delivery. Syntheses and biological studies are described of the first multidrug isocyanurate-based siderophore analogues separately containing one, two, and three 5-fluorouridine (5-FU) derivatives as the drug component. The results indicate that a single siderophore can be used to deliver multiple drugs to target pathogenic microorganisms. (C) 1999 Elsevier Science Ltd. All rights reserved.
• Iron Transport-Mediated Drug Delivery: Synthesis and Biological Evaluation of Cyanuric Acid-Based Siderophore Analogs and .beta.-Lactam Conjugates
  作者：Manuka Ghosh、Marvin J. Miller

  DOI：10.1021/jo00084a018

  日期：1994.3

  Trihydroxamate-containing isocyanurates 4a-c were synthesized and determined to be capable of substituting for natural siderophores (microbial iron sequestering agents) in limited microbiological assays. The direct coupling of protected 4a to carbacephalosporins 16 and 17 and subsequent deprotection gave conjugates 20 and 21. The Lorabid conjugate 21 was especially active against E. coli X580 in preliminary biological tests, thus demonstrating the continued potential of siderophore-mediated drug delivery.